Merck's Keytruda (pembrolizumab) Receives EC's Approval as 1L Treatment for Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer
Shots:
- The approval is based on pivotal P-III KEYNOTE-177 study involves assessing of Keytruda (200mg- q3w) vs CT regimen in 307 patients in a ratio (1:1) with previously untreated metastatic MSI-H or dMMR colorectal cancer
- Results: reduction in the risk of disease progression or death by 40%- median PFS (16.5mos. vs 8.2mos); ORR (44% vs 33%); CR (11% vs 4%) and PR (33% vs 29%); lower incidence of Grade ≥3 TRAEs (22% vs 66%)- and no new toxicities observed
- Keytruda is the 1st anti-PD-1/L1 therapy approved in Europe to treat MSI-H or dMMR Colorectal Cancer. Additionally- approval allows marketing in all 27 EU member states
Ref: Businesswire | Image: Merck
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com